ArticleCureus2026
Emergence of Two Rare Malignancies, Langerhans Cell Sarcoma and Myeloid Sarcoma, After Targeted Therapy for Chronic Lymphocytic Leukaemia: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic lymphocytic leukaemia (CLL), Langerhans cell sarcoma (LCS), and myeloid sarcoma are distinct haematological malignancies. While CLL is a common mature B-cell lymphoproliferative disorder, LCS and isolated myeloid sarcoma are rare entities that can present significant diagnostic and therapeutic challenges. We report the case of a patient with established CLL whose clinical condition deteriorated rapidly during treatment. Computed tomography (CT) imaging demonstrated the development of new masses that were initially suspicious for Richter's transformation. However, tissue biopsy confirmed the unexpected diagnosis of LCS. Chemotherapy for the LCS was commenced, initially demonstrating a favourable response. Three months later, the patient re-presented with pyrexia and new masses identified on repeat CT imaging. A further biopsy unexpectedly revealed myeloid sarcoma. Despite further investigation and management, the patient's condition continued to deteriorate, and they subsequently died from progressive disease. The sequential development of two exceptionally rare malignancies in a patient with CLL raises important questions regarding disease pathogenesis, clonal evolution, tumour surveillance, and the potential influence of novel targeted therapies. No
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.